Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Nazarov, Alexey A ^a,b   Baquié, Mathurin ^a   Nowak Sliwinska, Patrycja ^a,c   Zava, Olivier ^a   Van Beijnum, Judy R ^d   Groessl, Michael ^a   Chisholm, Danielle M ^e   Ahmadi, Zohrab ^e   Scott McIndoe, J ^e   Griffioen, Arjan W ^d   Van Den Bergh, Hubert ^a   Dyson, Paul J ^a  

^a EPFL   (Switzerland)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; RUTHENIUM;

ANGIOGENESIS; ANIMAL; ARTICLE; CELL CYCLE; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; CHICK EMBRYO; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; SYNTHESIS; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; ENDOTHELIAL CELLS; HUMANS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; RUTHENIUM;

EID: 84875786277     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01485     Document Type: Article

References (35)

1. Lippert, B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Verlag Helvetica Chimica Acta, (1999).
2. Dhar, S. & Lippard, S. J. Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs. In Bioinorg. Med. Chem. 79-95 (Wiley-VCH Verlag) (2011).
3. Wu, B., Davey, G. E., Nazarov, A. A., Dyson, P. J. & Davey, C. A. Specific DNA Structural Attributes Modulate Platinum Anticancer Drug Site Selection and Cross-Link Generation. Nucleic Acids Res. 39, 8200-8212 (2011).
4. Sava, G., Bergamo, A. & Dyson, P. J. Metal-based antitumour drugs in the postgenomic era: what comes next? Dalton Trans. 40, 9069-9075 (2011).
5. Jakupec, M. A., Galanski, M., Arion, V. B., Hartinger, C. G. & Keppler, B. K. Antitumor metal compounds: more than theme and variations. Dalton Trans., 183-194 (2008). (Pubitemid 350278321)
6. Hartinger, C. G.,Metzler-Nolte,N.&Dyson, P. J. Challenges andOpportunities in the Development of Organometallic Anticancer Drugs. Organometallics 31, 5677-5685 (2012).
7. Hartinger, C. G., Jakupec, M. A., Zorbas-Seifried, S., Groessl, M., Egger, A. & Bergar, W. KP1019, A New Redox-Active Anticancer Agent-Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chem. Biodiversity, 5, 2140-2155 (2008).
8. Sava, G., Gagliardi, R., Bergamo, A., Alessio, E. & Mestroni, G. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. Anticancer Res. 19, 969-972 (1999). (Pubitemid 29257523)
9. Chatterjee, S., Kundu, S., Bhattacharyya, A., Hartinger, C. & Dyson, P. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J. Biol. Inorg. Chem. 13, 1149-1155 (2008).
10. Nowak-Sliwinska, P., van Beijnum, J. R., Casini, A., Nazarov, A.,Wagnières, G. & van den Bergh, H. et al. Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity. J. Med. Chem. 54, 3895-3902 (2011).
11. Nowak-Sliwinska, P., Weiss, A., van Beijnum, J. R., Wong, T., Lovisa, B., Ballini, J. P. et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J. Cell. Mol. Med. 16, 1553-1562 (2012).
12. Astashkina, A., Mann, B. & Grainger, D. W. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Ther. 134, 82-106 (2012).
13. Kong, K. V., Leong,W. K., Ng, S. P., Nguyen, T. H. & Lim, L.H.Osmiumcarbonyl clusters: a new class of apoptosis inducing agents. Chem. Med. Chem. 3, 1269-1275 (2008).
14. Allardyce, C. S. & Dyson, P. J. The interactions of low oxidation state transition metal clusters with DNA: potential applications in cancer therapy. J. Cluster Sci. 12, 563-569 (2001). (Pubitemid 33637716)
15. Foresti, R., Bani-Hani, M. & Motterlini, R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med. 34, 649-658 (2008).
16. Alberto, R. & Motterlini, R. Chemistry and biological activities of CO-releasing molecules (CORMs) and transition metal complexes. Dalton Trans., 1651-1660 (2007). (Pubitemid 46633110)
17. Motterlini, R. et al. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ. Res. 90, E17-24 (2002).
18. Schatzschneider, U. Photoactivated Biological Activity of Transition-Metal Complexes. Eur. J. Inorg. Chem. 2010, 1451-1467 (2010).
19. Nazarov, A. A.&Dyson, P. J.Metal phosphorus complexes as antitumor agents. In Phosphorus Chemistry: Catalysis and Material Science Applications, Vol. 37 (eds. Gonsalvi, L. & Peruzzini, M.) 445-461 (Springer 2011).
20. Hartinger, C. G., Phillips, A. D. & Nazarov, A. A. Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics. Curr. Top. Med. Chem. 11, 2688-2702 (2011).
21. Blazina, D. et al. NMR Studies of Ru3(CO)10(PMe2Ph)2 and Ru3(CO)10(PPh3)2 and Their H2 Addition Products: Detection of New Isomers with Complex Dynamic Behavior. J. Am. Chem. Soc. 123, 9760-9768 (2001).
22. Deeming, A. J., Donovan-Mtunzi, S., Kabir, S. E. & Manning, P. J. New isomers of [Os3(CO)10(PMe2Ph)2] and [Os3(CO)9(PMe2Ph)3]. Dalton Trans. 1037-1041 (1985).
23. Crawford, E., Dyson, P., Forest, O., Kwok, S. & McIndoe, J. S. Energy-dependent Electrospray Ionisation Mass Spectrometry of Carbonyl Clusters. J. Cluster Sci. 17, 47-63 (2006). (Pubitemid 43695994)
24. Berger, I., Hanif, M., Nazarov, A. A., Hartinger, C. G., John, R. O. & Kuznetsov, M. L. et al. In Vitro Anticancer Activity and Biologically RelevantMetabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands. Chemistry Europ. Journal 14, 9046-9057 (2008).
25. Nazarov, A. A. et al. Anthracene-Tethered Ruthenium(II) Arene Complexes as Tools To Visualize the Cellular Localization of Putative Organometallic Anticancer Compounds. Inorg. Chem. 51, 3633-3639 (2012).
26. Hartinger, C. G., Nazarov, A. A., Ashraf, S. M., Dyson, P. J. & Keppler, B. K. Carbohydrate-Metal Complexes and their Potential as Anticancer Agents. Curr. Med. Chem. 15, 2574-2591 (2008).
27. Hanif, M.,Nazarov, A. A.,Hartinger, C. G., Kandioller, W., Jakupec, M. A., Arion, V. B., Dyson, P. J. & Keppler, B. K. Osmium(ii)-versus ruthenium(ii)-arene carbohydrate-based anticancer compounds: similarities and differences. Dalton Trans. 39, 7345-7352 (2010).
28. Hanif, M., Nazarov, A. A., Legin, A., Groessl, M., Arion, V. B., Jakupec, M. A., Tsybin, J. O., Dyson, P. J., Keppler, B. K. & Hartinger, H. G. Maleimidefunctionalised Organoruthenium Anticancer Agents for Tumour Targeting. Chem. Commun. 48, 1475-1477 (2012).
29. Dyson, P. J., Hearley, A. K., Johnson, B. F.G., McIndoe, J. S.&Langridge-Smith, P. R. R. UV laser desorption/ionisation mass spectrometry of the triruthenium clusters Ru3(CO)12-n(PPh3)n (n51, 2 and 3). Inorg. Chem. Commun. 2, 591-594 (1999).
30. Woo, H. Y. & Heo, J. Sorafenib in liver cancer. Expert Opin. Pharmacother. 13, 1059-1067 (2012).
31. Heng, D. Y. & Kollmannsberger, C. Sunitinib. Rec. Res. Cancer Res. 184, 71-82 (2010).
32. Hartmann, J. T.,Haap, M., Kopp, H. G.&Lipp, H. P. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10, 470-481 (2009).
33. Minick, D. J., Frenz, J. H., Patrick, M. A. & Brent, D. A. A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography. J. Med. Chem. 31, 1923-1933 (1988).
34. Nazarov, A. A., Risse, J., Ang, W. H., Schmitt, F., Zava,O.&Ruggi, A. Anthracenetethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. Inorg. Chem. 51, 3633-3639 (2012).
35. Nowak-Sliwinska, P., Ballini, J. P., Wagnieres, G. & van den Bergh, H. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc. Res. 79, 21-28 (2010).